Altimmune
Compare Altimmune…Clinical-stage biotech. Pemvidutide: GLP-1/glucagon dual agonist for obesity and MASH. Pivotal MASH IMPACT data expected 2026. MASH-first positioning differentiates from obesity-focused peers.
SectorsGLP-1
Register for a premium account to gain access to Sterling AI.
Get StartedThings you can ask Sterling:
AltimmuneClinical-stage biotech. Pemvidutide: GLP-1/glucagon dual agonist for obesity and MASH. Pivotal MASH IMPACT data expected 2026. MASH-first positioning differentiates from obesity-focused peers.
All metrics are vertically resized to show how they've changed over time. They're not on the same Y-axis. This chart is meant to compare trends, not values.
Values normalized to 0-100 scale for comparison. Hover for actual values.